Novartis Lays A New Foundation In Prostate Cancer With Second Radioligand Launch
"We have big plans," oncology president Susanne Schaffert said in an interview about launching Pluvicto, its new radioligand therapy for prostate cancer.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: Novartis builds radioligand therapy franchise; BMS pioneers new checkpoint inhibitors; Russian CRO leader tries to keep Ukraine trials going; Indian pharma and celebrity endorsement; and how R&D spend compares to 10 years ago.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CEO Vas Narasimhan committed to delivering compound annual growth of 4% from 2020-2026, driven by newer brands plus some pipeline assets.